Therapeutic approach could treat chronic low back pain
A targeted therapeutic approach could effectively treat chronic low back pain (cLBP), data suggests.
The Phase Ib trial of PP353, developed by biotechnology company Persica Pharmaceuticals, demonstrated a clinically meaningful and durable reduction in pain and disability in patients with chronic low back pain and Modic Type 1 changes. Results have been published in The Lancet’s eClinical Medicine.
Chronic low back pain is a disabling and debilitating disease that affects millions of people worldwide, who currently have limited effective treatment options. PP353, a novel, non-opioid, intradiscal therapy delivered directly to the site of infection, is the first targeted therapy for cLBP with Modic Type 1 changes.
Most patients with these Modic changes are not helped by existing standards of care and there is evidence that bacterial infection is the key contributor to pain in this subgroup. By addressing the infection, which is the root cause of the pain, rather than just the symptoms, PP353 could transform how this disease is treated.
Approximately 25% of patients with moderate to severe cLBP have Modic Type 1 changes, identifiable with an MRI scan. This equates to four million people in the US, Europe and Japan.
“Publication of our Phase 1b results in a prestigious journal is an important milestone for Persica and clear validation of our science and approach,” said Dr Steve Ruston, CEO of Persica Pharmaceuticals.
“Our goal is to develop a novel and impactful treatment for the millions of people living with chronic low back pain – a condition that causes debilitating pain, severely diminishes quality of life, and places a huge burden on healthcare systems and society.
“PP353 represents a genuinely innovative treatment modality that targets the underlying cause of disease, rather than just the symptoms. We are pleased that discussions with the FDA have provided a clear path to registrational studies and market approval.”
